Biotechnology Healis Therapeutics’ asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea – AbbVie (NYSE:ABBV) Read more
Biotechnology ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI) Read more